GSK Plc has agreed to buy Affinivax Inc. for as much as $3.3 billion, bolstering its vaccines pipeline as the U.K. pharmaceutical company prepares to split with its consumer-health unit.
To read the entire story, you must be logged in.
Please log in now or register with us.
